Mindaugas StoÅ;kus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/643400/publications.pdf Version: 2024-02-01

1937685 1872680 8 63 4 6 citations g-index h-index papers 10 10 10 174 docs citations times ranked citing authors all docs

MINDALICAS STOÅ:KUS

#	Article	IF	CITATIONS
1	ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia. Blood Cells, Molecules, and Diseases, 2016, 57, 30-34.	1.4	25
2	Defining the significance of IGF2BP1 overexpression in t(12;21)(p13;q22)-positive leukemia REH cells. Leukemia Research, 2016, 47, 16-21.	0.8	13
3	HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia. Journal of Oncology, 2019, 2019, 1-11.	1.3	8
4	Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclaxâ€based salvage therapies. European Journal of Haematology, 2021, 106, 105-113.	2.2	8
5	Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study. BMC Cancer, 2021, 21, 326.	2.6	4
6	Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia. Medicina (Lithuania), 2019, 55, 719.	2.0	3
7	Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission. Frontiers in Genetics, 2022, 13, 821676.	2.3	2
8	Population-based targeted RNA sequencing reveals novel disease-related gene fusions in pediatric and adult T-ALL. Leukemia Research, 2022, 116, 106825.	0.8	0